Wednesday IPO for Rockville’s Shuttle Pharmaceuticals
Rockville, Maryland-based Shuttle Pharmaceuticals, founded in 2012 by Georgetown University Medical Center faculty members, has raised just shy of $10 million in an initial public offering and will begin trading on the Nasdaq Capital Market under the ticker symbol SHPH on Aug. 31.
The Nasdaq Capital Market is one of three tiers for the Nasdaq’s U.S. markets, and focuses on early stage companies.
Shuttle Pharmaceuticals is developing treatments for cancer patients undergoing radiation therapy that reduce the side effects of radiation, while maximizing the treatment’s effectiveness.
The radiation sensitizers it is developing may enhance selective cell killing while better protecting normal cells.
Shuttle Pharmaceuticals will use the majority of the proceeds for Phase 2 clinical trials for its leading drug candidate, called Ropidoxuridine, in treatments for glioblastoma, an aggressive brain and spinal cord cancer, and sarcoma, a form of bone and soft tissue cancer.
Shuttle Pharma currently has two lead clinical-stage products and four preclinical products in development.